Ruti Aga's Six-Year Ban: How a Forged Prescription Closed the Last Window of Defence

The date 10 September appears twice in the Athletics Integrity Unit statement—once as the start of the provisional suspension, once as the anchor for a six-year ban. Reading Ruti Aga's case, the arithmetic arrived before the narrative: two years for the presence of a substance, four years for tampering with a document. Six in total. I have spent years reading road-race timing sheets and therapeutic-use paperwork; in cases like this, I look first at who was keeping the athlete's real records, before I look at the length of the sanction.

Aga is a 32-year-old Ethiopian marathoner. Her record includes the 2026 Tokyo Marathon title and three second-place finishes at World Marathon Majors. That is the bracket where a 2:18 to 2:20 runner gets selected for major races, and where the next selection list is always harder than the last. In March she won a half marathon in China. The source gives no time, no splits, no field strength. What it gives is a positive sample after that race, and an AIU statement on Thursday announcing a six-year ban.

Before London 2026 I built a qualifying-standards matrix. The matrix said London was ready; I asked who wrote the matrix. In Aga's case the question is not how fast she ran in March. The question is who wrote the knee-treatment document, who accepted it, and who was prepared to stand behind it as genuine.

The source calls methylprednisolone a prohibited steroid and says WADA classes it as performance enhancing. The classification is technically wrong. Methylprednisolone is a glucocorticoid, WADA Prohibited List class S9, not an anabolic steroid under S1. On the current List, S9 glucocorticoids are prohibited in-competition only, by injection, oral or rectal route. That distinction is not branding. It is the legal hinge of the case.

Intra-articular or peri-articular methylprednisolone for a knee is standard sports-medicine practice in distance runners. Out of competition, the treatment can be legal. In competition, residues become a violation. The defence route was therefore available: genuine medical records, a clear clinical justification, the route of administration, and enough washout time before the race. Instead, a family member wrote a prescription posing as a doctor.

According to the AIU statement, the clinic named on the prescription did not exist. The person who wrote it had no medical registration. He claimed to have used an old prescription pad from a former workplace, and the clinic explicitly disowned the document. Three separate verification failures. A forged prescription does not strengthen a defence; it closes the one route that genuine records could have kept open.

In the verification room the truth arrived in frames; on the track it arrived in breath. Here it arrived in a document. The AIU imposed two years for the presence violation and four years for tampering and misleading statements. The four-year element did not come from paper alone; it came from answers given in the investigation. That is what separates this case from a routine doping file. The athlete put her own account at risk while trying to protect the substance explanation.

The structure of the six-year sanction matters. Two years for a substance treated as specified under the WADA List, four years for conduct the Code calls tampering. The arithmetic tells us the panel rejected the no-significant-fault mitigation that could have reduced the presence sanction. With genuine medical records and a demonstrated clinical need, the presence charge might have been argued down to a reprimand or a much shorter period. The tampering charge would not have existed at all.

Backdating the ban to 10 September is a procedural benefit, not a reduction. Time served under provisional suspension counts against the ban. The real consequence is that a 32-year-old is out until roughly 38. Ethiopian women's marathon depth is so extreme that a 2:18 to 2:20 runner is not guaranteed selection even at her best. A 38-year-old returning with a doping record should expect the national-team door to be effectively closed.

There is a paradox I will not skip. There is no proven endurance benefit from glucocorticoids. Yet the ban runs six years. It is easy to call this AIU rigour and move on. For me, this is less a substance case than a document-verification case. Across East African road-running files, the first violation is often the substance and the second is the explanation—an altered prescription, a misleading interview, a document that cannot survive checking.

The second layer is medical governance. An athlete with a credentialed team doctor would have logged a knee injection with a TUE or a route-specific washout. Here the medical support looks informal and familial. Chronic knee pathology is a known load-bearing failure mode in high-volume marathoners. Pain masking, appearance-fee contracts and cheap treatment combine to create an environment where keeping real records is not a habit.

China's label-race circuit sits inside this story. For East African marathoners it is a reliable income tier between Majors. It is also becoming one of the AIU's highest-yield testing grounds. The appearance-fee economy and the testing economy are colliding in the same races. The March result and prize money are very likely to be annulled, although the source does not state the disqualification scope.

The Ethiopian federation's response is absent from the report. Only the AIU is quoted. That silence matters. When a national federation says nothing about a six-year ban on one of its athletes, the message is that the case belongs to the athlete and her entourage, not to the system. My next question is whether anyone examined the role of an agent, coach or manager in producing or accepting the forged prescription. The AIU statement names only the family member.

An appeal route exists, typically around 21 days from the reasoned decision. Overturning a document-based tampering finding is hard. The more plausible fight is over procedure or the admissibility of interview statements. In my experience, such cases are won with real records. Here the centre of the file is a fake one.

Indian road running should take a direct lesson. Many athletes manage a season through small clinics, local doctors and informal injections. Without a recorded medical file, a positive sample can put them in the same place as Aga. Protocol is memory written down—which is why institutions fear it. For an athlete, that memory has to look like a real prescription, a real date, a real doctor and a real route.

Eleven weeks of phone calls taught me more than a season of press conferences. During the 2026 shutdown, the lesson was that an athlete's real protection is the paperwork she holds—contracts, funding letters, camp lists, medical files. Had Aga held those, this might have been a two-year story, or no case at all.

The next story is not when Aga races again. The next story is whether the March result is annulled, whether a CAS appeal is filed, and whether the Ethiopian federation breaks its silence. When those three answers arrive, we will know whether this was one athlete's mistake or a system's.